Ishares Nasdaq Biotechnology (IBB)

(A Top Pick Nov. 17/17, Up 7%) There was a three for one stock split. This and healthcare are in a long term secular bull market. You have to live with the volatility and this is why he likes the ETF. He would hold it long term.

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

(A Top Pick September 21 / 2017, Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices.

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

When looking at sector rotation, biotech technology to a certain degree, is sort of in the middle. The strong rotation we’ve seen has been in industrials, energy and financials, but healthcare is sort of in the middle. This is at a good level to step in. Not for the faint of heart.

This is a long-term theme. We are going to have a little bit of resistance at his initial target of $3.90. (Chart actually shows around $380. Did he misspeak? - Bill) There is some volatility with some pretty big swings.

He is very positive on the biotech sector. There had been a lot of negative news cycle during the election, so the sector consolidated for some time. He then got back in through this ETF in March. He just sold this, but only because of a portfolio rebalancing. A great way to play Biotech’s.

(Top Pick Jun 28/17, Down 4.04%) Season strength is June to September for Biotech. It is the ramp up ahead of cold and flu season. It broke a significance line and we are re-testing it. Momentum has come out of the name in the last three weeks. There is the continuous overhang of high drug prices in the US. If it cannot hold $300 then get out of it. It is no longer supported as a seasonal trade and he would get out of it.